Outlook Therapeutics announces UK MHRA marketing authorisation of Lytenava (bevacizumab gamma) for the treatment of wet AMD

Outlook Therapeutics

8 July 2024 - Initial commercial launches of Lytenava (bevacizumab gamma) in the EU and UK anticipated in calendar Q1, 2025.

Outlook Therapeutics today announced that the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for Lytenava (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration in the UK.

Read Outlook Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , England , Medicine , Biosimilar